Literature DB >> 3032152

Mechanism of inhibition of mammalian DNA topoisomerase I by heparin.

K Ishii, S Futaki, H Uchiyama, K Nagasawa, T Andoh.   

Abstract

We have previously shown that heparin is a potent inhibitor of a mammalian DNA topoisomerase I. We have now investigated the mechanism of its inhibition. This was carried out first by scrutinizing the structural features of heparin molecules responsible for the inhibition. Commercial heparin preparation was fractionated by antithrombin III-Sepharose into non-adsorbed, low-affinity and high-affinity fractions, of which only the high-affinity fraction of heparin is known to contain a specific oligosaccharide sequence responsible for the binding to antithrombin III. These fractions all exhibited essentially similar inhibitory activities. Furthermore, when chemically sulphated to an extent comparable with or higher than heparin, otherwise inactive glycosaminoglycans such as heparan sulphate, chondroitin 4-sulphate, dermatan sulphate and neutral polysaccharides such as dextran and amylose were converted into potent inhibitors. Sulphated dermatan sulphate, one of the model compounds, was further shown to bind competitively to the same sites on the enzyme as heparin. These observations strongly suggested that topoisomerase inhibition by heparin is attributable primarily, if not entirely, to the highly sulphated polyanionic nature of the molecules. In a second series of experiments we examined whether heparin inhibits only one or both of the topoisomerase reactions, i.e. nicking and re-joining. It was demonstrated that both reactions were inhibited by heparin, but the nicking reaction was more severely affected than was the re-joining reaction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032152      PMCID: PMC1147532          DOI: 10.1042/bj2410111

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  A note on the determination of the ester sulphate content of sulphated polysaccharides.

Authors:  K S DODGSON; R G PRICE
Journal:  Biochem J       Date:  1962-07       Impact factor: 3.857

2.  The inhibition of elongation factor 1 activity by heparin.

Authors:  L I Slobin
Journal:  Biochem Biophys Res Commun       Date:  1976-12-06       Impact factor: 3.575

3.  Folding of the DNA double helix in chromatin-like structures from simian virus 40.

Authors:  J E Germond; B Hirt; P Oudet; M Gross-Bellark; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

4.  The separation of active and inactive forms of heparin.

Authors:  L H Lam; J E Silbert; R D Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1976-03-22       Impact factor: 3.575

5.  Replication of colicin E1 plasmid DNA in cell extracts.

Authors:  Y Sakakibara; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

6.  Inhibition by heparin of globin messenger rbinucleic acid translation in a mammalian cell-free system.

Authors:  A A Waldman; J Goldstein
Journal:  Biochemistry       Date:  1973-07-03       Impact factor: 3.162

7.  Interaction between DNA and an Escherichia coli protein omega.

Authors:  J C Wang
Journal:  J Mol Biol       Date:  1971-02-14       Impact factor: 5.469

8.  Heparin-lipoprotein lipase interactions.

Authors:  T Olivecrona; G Bengtsson; S E Marklund; U Lindahl; M Höök
Journal:  Fed Proc       Date:  1977-01

Review 9.  Chemistry of the hemostatic mechanism and its relationship to the action of heparin.

Authors:  R D Rosenberg
Journal:  Fed Proc       Date:  1977-01

10.  Establishment of cell lines in vitro from a mammary ascites tumor of mouse and biological properties of the established lines in a serum containing medium.

Authors:  N Nakano
Journal:  Tohoku J Exp Med       Date:  1966-01-25       Impact factor: 1.848

View more
  9 in total

1.  Purification and characterization of PCR-inhibitory components in blood cells.

Authors:  W A Al-Soud; P Rådström
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 2.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

Review 3.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.

Authors:  T Andoh; K Ishii; Y Suzuki; Y Ikegami; Y Kusunoki; Y Takemoto; K Okada
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  DNA topoisomerase I from Alcaligenes eutrophus H16.

Authors:  L Andĕra; K Mikulík
Journal:  Arch Microbiol       Date:  1990       Impact factor: 2.552

6.  Selective inhibition of bacterial and human topoisomerases by N-arylacyl O-sulfonated aminoglycoside derivatives.

Authors:  Amanda M Fenner; Lisa M Oppegard; Hiroshi Hiasa; Robert J Kerns
Journal:  ACS Med Chem Lett       Date:  2013-05-09       Impact factor: 4.345

7.  Topoisomerase I inhibitors and drug resistance.

Authors:  R E Parchment; A Pessina
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

8.  Electrostatic binding of polyanions using self-assembled multivalent (SAMul) ligand displays - structure-activity effects on DNA/heparin binding.

Authors:  Loryn E Fechner; Buthaina Albanyan; Vânia M P Vieira; Erik Laurini; Paola Posocco; Sabrina Pricl; David K Smith
Journal:  Chem Sci       Date:  2016-04-18       Impact factor: 9.825

9.  Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action.

Authors:  József Dudás; József Bocsi; Alexandra Fullár; Kornélia Baghy; Tibor Füle; Saule Kudaibergenova; Ilona Kovalszky
Journal:  Biomed Res Int       Date:  2014-09-07       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.